Search

Displaying results 1461 - 1470 of 3733 in total
  1. Drug

    PD-168393

    go.drugbank.com/drugs/DB07662
    Experimental

    PD-168393 is an epidermal growth factor receptor inhibitor.

  2. Drug

    PD-98059

    go.drugbank.com/drugs/DB17042
    Experimental

    PD-98059 is an inhibitor of MAP-kinase kinase activation.[A253072]

  3. Drug

    PF-04447943

    go.drugbank.com/drugs/DB11953
    Investigational

    PF-04447943 has been investigated for the treatment of Alzheimer's Disease.

  4. Drug

    PF-00446687

    go.drugbank.com/drugs/DB12517
    Investigational

    PF-00446687 has been investigated for the treatment of Erectile Dysfunction.

    Categories: Receptor, Melanocortin, Type 4, agonists
  5. Drug

    Inotuzumab ozogamicin

    go.drugbank.com/drugs/DB05889
    ApprovedInvestigational

    Inotuzumab ozogamicin is an antibody-drug conjugate consisting of a humanized IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide. The antibody por...

    Categories: P-glycoprotein substrates, P-glycoprotein substrates with a Narrow Therapeutic Index
  6. Drug

    Stannous fluoride

    go.drugbank.com/drugs/DB11092
    ApprovedInvestigational

    It is an FDA-approved over-the-counter product.

    Products: Stan-gard Gel 0.4%, 1.64% Stan. Fluor. Office Rinse Concentrate
  7. Drug

    Triflusal

    go.drugbank.com/drugs/DB08814
    ApprovedWithdrawn

    The benefits of this agent are the lack of action over the arachidonic acid pathway, the driven production of nitric oxide and the increase of cyclic nucleotide concentration on endothelial cells.

  8. Drug

    Omadacycline

    go.drugbank.com/drugs/DB12455
    ApprovedInvestigational

    Omadacycline represents a significant advance over the well-known tetracycline family, and has been shown to be highly effective in animal models at treating increasingly problematic, clinically prevalent

    Categories: P-glycoprotein substrates
  9. Drug

    KD7040

    go.drugbank.com/drugs/DB05214
    Investigational

    KD7040 is a topically-delivered inducible nitric oxide synthase (iNOS) inhibitor for the treatment of neuropathic pain. The KD7040 IND was filed in 4Q06, and a Phase Ib clinical trial began 2Q07. It is being developed by Kalypsys.

  10. Drug

    PF-00217830

    go.drugbank.com/drugs/DB12998
    Investigational

    PF-00217830 has been used in trials studying the treatment of Schizophrenia.